Stocks › TGTX

TG THERAPEUTICS, INC.

TGTX·Nasdaq·United States United States·USD
$63.34
-1.54 (-2.37%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
TGTX
TG THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
TGTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of TGTX by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Christopher L. JacobsChristopher L. JacobsHouse · R · NY TGTXTG THERAPEUTICS, INC. · Stock Sale
$1,001 - $15,000
Nov 6, 2020 Sep 8, 2020 Filing ↗

Whale Activity

Position changes in TGTX reported for 2026-09-30 by 500 institutional filers
Increased: 165New: 73Held: 65Decreased: 131Closed: 44No prior filing: 22
  • Increased165
  • New73
  • Held65
  • Decreased131
  • Closed44
  • No prior filing22
FilerSharesValueChange
BlackRock, Inc.22.6M$1.26Bincreased
STATE STREET CORP8.5M$473.5Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC7.9M$439.6Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC6.3M$349.0Mincreased
GEODE CAPITAL MANAGEMENT, LLC3.7M$206.6Mincreased
TWO SIGMA INVESTMENTS, LP3.4M$188.0Mincreased
D. E. Shaw & Co., Inc.3.3M$182.9Mdecreased
CONGRESS ASSET MANAGEMENT CO2.6M$145.4Mincreased
Soleus Capital Management, L.P.2.6M$142.6Mdecreased
GOLDMAN SACHS GROUP INC2.5M$139.5Mincreased
BARCLAYS PLC2.4M$135.2Mincreased
Clearbridge Investments, LLC2.1M$119.4Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by TGTX insiders, by quarter · Form 4
-25.0K-12.5K012.5K25.0K2025 Q1: -21.4K2025 Q12025 Q2: -10.0K2025 Q22025 Q3: -20.9K2025 Q32025 Q4: -5,0002025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: -5,0002026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

195 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Charney Laurence NDirector Sale −5,000 $54.96 $275K Sep 10, 2026 Form 4 ↗
Charney Laurence NDirector Gift −450 $0.00 $0 Aug 7, 2026 Form 4 ↗
Charney Laurence NDirector Gift −500 $0.00 $0 Aug 7, 2026 Form 4 ↗
Charney Laurence NDirector Gift −5,100 $0.00 $0 Aug 6, 2026 Form 4 ↗
Charney Laurence NDirector Gift −13.2K $0.00 $0 Jan 29, 2026 Form 4 ↗
Charney Laurence NDirector Gift −30.0K $0.00 $0 Jan 28, 2026 Form 4 ↗
WEISS MICHAEL SCEO · Director Grant / award +622.0K $0.00 $0 Jan 8, 2026 Form 4 ↗
Power Sean ACFO Grant / award +90.0K $0.00 $0 Jan 8, 2026 Form 4 ↗
Echelard YannDirector Sale −5,000 $32.57 $163K Nov 24, 2025 Form 4 ↗
WEISS MICHAEL SCEO · Director Gift −803.7K $0.00 $0 Nov 5, 2025 Form 4 ↗
WEISS MICHAEL SCEO · Director Gift −3.9M $0.00 $0 Nov 5, 2025 Form 4 ↗
Lonial SagarDirector Sale −20.9K $32.24 $672K Sep 11, 2025 Form 4 ↗
Echelard YannDirector Sale −10.0K $36.94 $369K Jun 13, 2025 Form 4 ↗
Echelard YannDirector Grant / award +14.7K $0.00 $0 Jun 12, 2025 Form 4 ↗
Charney Laurence NDirector Grant / award +21.4K $0.00 $0 Jun 12, 2025 Form 4 ↗
Hoberman KennethDirector Grant / award +14.7K $0.00 $0 Jun 12, 2025 Form 4 ↗
HUME DANIELDirector Grant / award +14.7K $0.00 $0 Jun 12, 2025 Form 4 ↗
Lonial SagarDirector Grant / award +14.7K $0.00 $0 Jun 12, 2025 Form 4 ↗
HUME DANIELDirector Gift −62.5K $0.00 $0 Mar 17, 2025 Form 4 ↗
Charney Laurence NDirector Gift −6,000 $0.00 $0 Mar 10, 2025 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding TGTX · SEC Form N-PORT
FundSharesValue% of fundAs of
iShares Core S&P Small-Cap ETF
iShares Trust
7.9M$436.2M0.39%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
4.4M$240.5M0.01%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
3.7M$205.3M0.25%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
3.2M$173.7M0.09%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
2.1M$117.3M1.09%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
1.8M$100.0M0.21%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.5M$83.0M0.09%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.6M$82.8M0.24%Jul 31, 2026
iShares Russell 2000 Growth ETF
iShares Trust
1.3M$73.8M0.48%Jun 30, 2026
Congress Small Cap Growth Fund
Professionally Managed Portfolios
1.3M$67.6M3.37%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list TGTX's shares (CUSIP 88322Q108), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 21.2M shares13.8%
    Oct 27, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming TG THERAPEUTICS, INC. as client

No lobbying filings found naming TG THERAPEUTICS, INC. as the client.

Government Contracts

Federal awards to TG THERAPEUTICS, INC. · USAspending

No federal contract awards found for TG THERAPEUTICS, INC..

U.S. Patents

Recent USPTO applications naming TG THERAPEUTICS, INC.

No USPTO patent applications found for TG THERAPEUTICS, INC..

Annual Financials

From TGTX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$616.3M$329.0M$233.7M$2.8M$6.7M
Operating income$123.3M$41.9M$20.6M-$218.3M-$344.8M
Net income$447.2M$23.4M$12.7M-$223.8M-$348.1M
Diluted EPS$2.77$0.15$0.09-$1.65-$2.63
Operating cash flow-$24.8M-$40.5M-$31.4M-$176.2M-$295.6M
Cash and equivalents$79.1M$179.9M$92.9M$102.3M$298.9M
Total assets$1.06B$577.7M$329.6M$193.6M$379.6M
Total liabilities$415.2M$355.3M$169.1M$135.0M$142.5M
Shareholders' equity$648.0M$222.4M$160.5M$58.6M$237.2M

As TG THERAPEUTICS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 27, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 3-for-169Reverse splitApr 30, 2012
  • 1-for-50Reverse splitJul 14, 2011

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 12, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 3, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsMay 27, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
    EDGAR ↗

About TG THERAPEUTICS, INC.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNEW YORK, NY
IncorporatedDE
Former namesMANHATTAN PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, ATLANTIC PHARMACEUTICALS INC